TWiV explains why this season’s influenza vaccine is not protecting against mild to moderate disease caused by H3N2 virus, and that antibody-dependent entry of SARS-CoV-2 into monocytes is a major contributor to severe COVID-19.
The Fellowship of the Virus discuss enhancement of dengue disease in humans: the contribution of antibody concentration and increased binding to Fc receptors. <span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span>&lt;span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”&gt;&lt;/span&gt;&amp;lt;span data-mce-type=”bookmark” …
TWiV 473: Assessing a risk and infecting you twice Read More »
Severe dengue virus disease, also known as dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), is most likely to occur in previously infected individuals experiencing a second encounter with a different serotype. A specific range of serum antibody titers has been shown to enhance viral replication in cell culture and in animal models, and now in humans.
The short answer to the question posed in the title of this blog is: we don’t know. Why would we even consider that a prior dengue virus infection would increase the severity of a Zika virus infection? The first time you are infected with dengue virus, you are likely to have a mild disease involving …
Does prior dengue virus infection exacerbate Zika virus disease? Read More »
Flaviviruses are unusual because antibodies that cross-react with different viruses can enhance infection and disease. This property, called antibody-dependent enhancement or ADE, has been documented to occur among the four serotypes of dengue virus. It has implications for infection with or vaccination against Zika virus or dengue virus. Earlier this year (virology blog link) it was …
